Delivery Order SPE2DB24D2100-SPE2DB25FBFXW
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $10,304.26. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement practices. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $42,751.81. This non-set-aside delivery order is expected to be completed by August 1, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a child award under the company's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Gemtesa 75 mg tablets (90-count packages) under a firm fixed-price contract with a ceiling value of $14,925.47. This non-set-aside award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order has an ultimate completion date of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Gemtesa 75 mg tablets (90-unit quantity) with a ceiling value of $8,291.23. This firm fixed-price delivery order, with an ultimate completion date of August 4, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Gemtesa 75 mg tablets (90-count packaging) with a ceiling value of $3,197.73. This firm fixed-price delivery order, which is expected to be completed by August 20, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026). The award was made through...
- The Defense Logistics Agency awarded a delivery order valued at $3,869.18 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count supply) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a $4,983.09 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units), with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $7,747.10 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90 count) on August 12, 2025, with completion scheduled for August 13, 2025. This competitively awarded, firm fixed price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 8, 2025, with a ceiling value of $3,831.81 and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $48,882.83 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count units) with a performance location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-asides and carries an ultimate completion date of August 18, 2025. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBFXWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed price arrangement with a ceiling value of $28,746.00. This non-set-aside competitive award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle running through December 2026. The ultimate completion date for this delivery order is August 21, 2025, with performance occurring at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. The company's extensive portfolio of federal contracts demonstrates its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains, from specialty medications and brand-name drugs to vaccines and medical supplies. This delivery order for Gemtesa, a medication used in urological treatment, exemplifies the company's role as a prime vendor supplying essential pharmaceuticals to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.7k | 8/20/25 |